Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rubinstein, E.
Right arrow Articles by Camm, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rubinstein, E.
Right arrow Articles by Camm, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 593-596
© 2002 The British Society for Antimicrobial Chemotherapy

Leading article

Cardiotoxicity of fluoroquinolones

Ethan Rubinsteina,* and John Cammb

a Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer 52621, Israel; b St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK

Currently marketed fluoroquinolones enjoy an admirable safety profile that is not matched by any other antibiotic group. The widespread use of fluoroquinolones in the elderly, who are susceptible to cardiac arrhythmias because of underlying heart diseases, metabolic derangement and use of anti-arrhythmic agents and other medications that prolong the QT interval, has raised the issue of the cardiac safety of the newer fluoroquinolones. This issue had been further stressed by the unexpected removal from the market of several fluoroquinolones because of safety issues, including cardiotoxic effects. A recent leading article addressed this issue, and the aim of the present article is to update the reader on this matter.1

How frequent is torsade de pointes (TdP)? A WHO report from 1983–1999 reported 761 cases, with 34 (4.8%) being fatal. Beerman, in Sweden, in a 1 month survey of 32 hospitals serving 4.2 million inhabitants, reported 68 episodes of ventricular tachycardia, of . . . [Full Text of this Article]

Sparfloxacin

Grepafloxacin

Levofloxacin

Gatifloxacin

Moxifloxacin

Gemifloxacin

BMS-284756

Conclusions

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
G. J. Noel, D. B. Goodman, S. Chien, B. Solanki, M. Padmanabhan, and J. Natarajan
Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings
J. Clin. Pharmacol., May 1, 2004; 44(5): 464 - 473.
[Abstract] [Full Text]

Home page
 Journal of Pharmacy PracticeHome page
K. M. Smith and B. M. Lomaestro
What Role do Fluoroquinolone Antimicrobial Agents Play in Cardiac Dysfunction and Altered Glycemic Control?
Journal of Pharmacy Practice, October 1, 2003; 16(5): 349 - 360.
[Abstract] [PDF]